The next generation of the company's leading
single cell technology architecture, GEM-X, enables higher
performance at larger scale and lower cost
PLEASANTON, Calif., March 13,
2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, announced today
that it has started shipping the first two products powered by the
GEM-X technology architecture, Chromium Single Cell Gene Expression
3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the
next generation of the company's leading single cell technology
architecture and is built on a new and improved microfluidic chip
design, featuring the latest technological advancements and
optimized reagents for superior performance and high
reliability.
"It's been incredible to see the enthusiasm from customers since
we first announced the GEM-X architecture last month, and we can't
wait to get these new products in researchers' hands," said
Michael Schnall-Levin, Founding
Scientist and Chief Technology Officer of 10x Genomics. "GEM-X sets
a new standard for single cell analysis and gives customers
important performance advantages that will immediately benefit
their research. This is one of multiple steps we have planned to
make single cell more accessible for all."
GEM-X is exclusively available for use on Chromium X Series
instruments and delivers important performance and workflow
advantages, including:
- Substantially increased sensitivity: Detect up to two
times more genes compared to on-market Chromium assays to gain a
more comprehensive view of cellular heterogeneity
- Built to scale: Two-fold increase in cells captured per
channel
- More cost effective: More than two-fold reduction in
cost per cell
- Enhanced data quality: Two-fold reduction in multiplet
rate enabling high quality data at scale
- Maximum sample recovery: Recovery of up to 80% of cells,
improving capture efficiency and making it ideal for samples
typically yielding few cells, such as tissue biopsies or previously
flow sorted cells
- Improved assay robustness: Redesigned microfluidics and
optimized reagents for faster and more efficient cell
partitioning
"Selecting the optimal assay for single-cell experiments is
challenging. However, it's evident that identifying more genes per
cell enriches our understanding of cellular functions and the
intricacies of biology," said Luciano Martelotto, Associate
Professor at the University of Adelaide. "GEM-X, with its exceptional
transcript capture, can enhance our capacity to differentiate cell
types, spot rare cells and decode regulatory pathways. Improved
accuracy in transcriptome data further facilitates the seamless
integration of single-cell findings from diverse research projects
and platforms."
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, costs, capabilities, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-begins-commercial-shipments-of-chromium-gem-x-products-302088504.html
SOURCE 10x Genomics, Inc